812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer

Bibliographic Details
Main Authors:	Hao Wang, Elizabeth Thompson, Lei Zheng, Dung Le, Christopher Wolfgang, Robert Anders, Jin He, Carol Judkins, Jessica Hoare, Rachel Klein, Rose Parkinson, Haihui Cao, Jennifer Durham, Katrina Purtell, Ana De Jesus-Acosta, Amol Narang, Richard Burkhart, William Burns, Daniel Laheru
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Description
ISSN:	2051-1426

Similar Items